Effects of ruxolitinib topical: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of ruxolitinib topical
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of ruxolitinib topical: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of ruxolitinib topical: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Ruxolitinib topical is an effective treatment for vitiligo, an autoimmune condition causing skin depigmentation. 9 , 5 , 8 In two phase 3 trials, 52% of patients experienced a 75% or more improvement in their Facial Vitiligo Area Scoring Index (F-VASI), demonstrating its efficacy in restoring skin color. 5 , 8 Additionally, ruxolitinib topical is also effective in treating atopic dermatitis, a common inflammatory skin condition characterized by dry, itchy skin. 2 , 3 , 13 , 11 , 7 , 12 , 10 Ruxolitinib topical has demonstrated improvement in skin lesions and reduction in itchiness in patients with atopic dermatitis. 7 , 12 Furthermore, compared to oral forms of this medicine, ruxolitinib topical offers a better safety profile with fewer systemic side effects. 13

Benefits and Risks

Benefit Summary

Ruxolitinib topical has emerged as a potential treatment option for various skin conditions like vitiligo and atopic dermatitis. 9 , 5 , 8 , 2 , 3 , 13 , 11 , 7 , 12 , 10 In vitiligo, it shows promising results in restoring skin pigmentation and reducing the visibility of depigmented patches. 9 , 5 , 8 For atopic dermatitis, it helps alleviate skin inflammation and itchiness, improving the overall quality of life for patients. 7 , 12 Furthermore, ruxolitinib topical offers a safer alternative compared to oral JAK inhibitors, with a lower risk of systemic side effects. 13

Risk Summary

While generally considered safe, ruxolitinib topical can have side effects. 8 Common side effects include acne, redness, and itching at the application site, inflammation of the throat and nasal passages, headaches, and fever. 8 It is not recommended for pregnant or breastfeeding women. 5

Comparison between Studies

Commonalities

Several studies have shown that ruxolitinib topical is an effective treatment for vitiligo and atopic dermatitis. 9 , 5 , 8 , 2 , 3 , 13 , 11 , 7 , 12 , 10 These studies consistently demonstrate that ruxolitinib topical outperforms placebo in improving the condition.

Differences

The effectiveness of ruxolitinib topical may vary depending on the type and severity of the skin condition. 8 Additionally, individual patients may experience different side effects from ruxolitinib topical. 8

Consistency and Contradictions in Results

Multiple studies consistently indicate that ruxolitinib topical is an effective treatment for vitiligo and atopic dermatitis. 9 , 5 , 8 , 2 , 3 , 13 , 11 , 7 , 12 , 10 However, further research is necessary to establish the optimal dosage, duration of treatment, and long-term effects of ruxolitinib topical.

Real-World Applications and Precautions

It is essential to use ruxolitinib topical as directed by a healthcare professional. 5 Avoid self-treating or using it with other medications without consulting a doctor. 5 If any adverse effects occur during treatment, seek immediate medical attention. 8

Limitations of Current Research

The long-term safety of ruxolitinib topical requires further investigation. 5 Moreover, ruxolitinib topical is not recommended for pregnant or breastfeeding women. 5

Future Research Directions

Large-scale clinical trials are necessary to evaluate the long-term safety and efficacy of ruxolitinib topical. 5 Additional research is needed to determine the optimal dosage, duration of treatment, and any potential long-term effects. 5

Conclusion

Ruxolitinib topical is a promising new treatment for vitiligo and atopic dermatitis, offering potential for improved skin health and quality of life. 9 , 5 , 8 , 2 , 3 , 13 , 11 , 7 , 12 , 10 However, further research is necessary to fully understand its long-term safety and effectiveness. Consult with a doctor before considering ruxolitinib topical. 5

Literature analysis of 13 papers
Positive Content
13
Neutral Content
0
Negative Content
0
Article Type
1
2
2
6
12
1.

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.

Author: ZhangRui, HouQin-Chuan, LiBing-Hong, DengLing, YangYu-Mei, LiTing-Xin, YaoXiao-Qin, YangLiang-Liang, LinXi-Long, LiaoYi-Qian, WangLin, LiuYu-Ping, TanJing, WanZheng-Wei, ShuaiPing

Semaglutide efficacy
Weight reduction

Semaglutide is effective for weight reduction, but the optimal dosage and frequency of administration are unclear. This study explores the effects of different semaglutide administration regimens on weight control.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Novel Vehicles For Drug Delivery in Atopic Dermatitis: A Narrative Review.

Author: FarkouhChristopher, AnthonyMichelle, AbdiParsa, SantiagoNatalia, FarkouhMatthew

Improved AD treatment
Steroid side effects

Atopic dermatitis is a common skin condition, and topical corticosteroids are the standard treatment, but they can have side effects. This article discusses the need for new drugs and drug delivery methods to treat atopic dermatitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 3: Roflumilast.

Author: DiRuggieroMargaret, Mancuso-StewartElizabeth, DiRuggieroDouglas, ZirwasMatt

Dermatitis treatment
Non-steroidal topicals
None mentioned

Topical roflumilast is a highly potent phosphodiesterase-4 inhibitor that has recently been approved by the FDA for the treatment of plaque psoriasis. This review summarizes the data surrounding topical roflumilast, providing an overview of its unique mechanism of action, clinical characteristics, efficacy, safety, and tolerability profiles.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders.

Author: Corbella-BagotL, Riquelme-McLoughlinC, Morgado-CarrascoD

Effective treatment
Favorable safety profile

This narrative review examines the long-term safety profile of currently approved JAK inhibitors for dermatological use, including upadacitinib, baricitinib, abrocitinib, and topical ruxolitinib. The review explores the off-label use of these drugs in various skin disorders.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.

Author: GrossmannMeghan C, HaidariWasim, FeldmanSteven R

Repigmentation
Cost

Topical ruxolitinib is the first medication approved for repigmentation in patients with vitiligo. In two 52-week phase 3 trials, 52.0% of subjects had at least 75% improvement in their Facial Vitiligo Area Scoring Index (F-VASI).

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Topical ruxolitinib: A new treatment for vitiligo.

Author: TavolettiG, AvalloneG, ConfortiC, RoccuzzoG, MaroneseC A, MattioliM A, QuaglinoP, ZalaudekI, MarzanoA V, RiberoS, Alberti-ViolettiS

Vitiligo treatment

This review summarizes the current evidence concerning the efficacy and safety of topical ruxolitinib, a JAK1/2 inhibitor, in the treatment of vitiligo. Based on phase III clinical trials, topical ruxolitinib demonstrated promising results in treating non-segmental vitiligo, offering a potential treatment option for patients with this chronic skin disorder.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review.

Author: SadeghiSara, MohandesiNessa Aghazadeh

Improved EASI
IGA
pruritus
Topical JAKi for AD
Mild-to-moderate adverse effects

This systematic review examined the efficacy and safety of topical Janus Kinase inhibitors (JAKis) for the treatment of atopic dermatitis (AD). The review found that topical JAKis were effective in treating AD in adults and children, with minimal risk of mild-to-moderate adverse effects.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

New Topical Therapies in Development for Atopic Dermatitis.

Author: FreitasEgídio, GooderhamMelinda, TorresTiago

Treat atopic dermatitis

This review discusses topical treatments for atopic dermatitis (AD), highlighting the limitations of current therapies like corticosteroids and calcineurin inhibitors. The authors examine the potential of new topical compounds, including ruxolitinib, tapinarof, difamilast, and roflumilast, for treating mild to moderate AD. However, they emphasize the need for larger, long-term studies to assess their efficacy and safety.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.

Author: BissonnetteRobert, CallRobert S, RaoofTooraj, ZhuZhaoyin, YeleswaramSwamy, GongXiaohua, LeeMark

Good tolerability
High efficacy
Adverse events

This open-label, maximum-use phase I study determined the safety, tolerability, and bioavailability of 1.5% ruxolitinib cream in patients with atopic dermatitis. Ruxolitinib cream was generally well tolerated, with a high level of efficacy in patients with atopic dermatitis involving ≥ 25% affected body surface area.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.

Author: GongXiaohua, ChenXuejun, KuligowskiMichael E, LiuXing, LiuXiang, CiminoEvan, McGeeRyan, YeleswaramSwamy

No systemic effects
None reported

Topical ruxolitinib cream for atopic dermatitis did not lead to systemic plasma concentrations associated with adverse effects commonly seen with oral JAK inhibitors.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.